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Introduction 
The advent of inhaled corticosteroid treatment facili- 
tated a shift in the management of asthma from a 
primarily symptomatic approach (treatment of acute 
attacks) to a preventative approach with emphasis on 
control of symptoms and prevention of acute attacks. 
The most recent guidelines from the U.S. National 
Asthma Education and Prevention Program promote 
the early use of inhaled corticosteroids for all asthma 
patients, except those with m ild intermittent disease, 
in order to prevent lung damage (1). Similarly, 
updated British Asthma Guidelines advocate aggres- 
sive use of inhaled corticosteroids (2,3). For example, 
in contrast to the former approach of gradually 
increasing the dosage of inhaled corticosteroid until 
symptoms are controlled, it is recommended that 
early treatment be initiated with higher dosages and 
then tapered to the lowest effective dosage. Also, 
inhaled corticosteroids are listed with sodium cromo- 
glycate for initial prophylaxis of asthmatic children 
aged < 5 years; previously they were only recommended 
in this patient population after an unsuccessful trial 
of sodium cromoglycate. 
Beclomethasone dipropionate (BDP) was the first 
inhaled corticosteroid introduced into the market- 
place. Since then others have been licensed for clinical 
use. Currently, budesonide and BDP are the most 
widely prescribed inhaled corticosteroids in the U.K. 
and high-dose formulations of these drugs are being 
prescribed with ever-increasing frequency in countries 
where they are available (4). A number of studies have 
been conducted directly comparing the efficacy of 
these two agents in asthma and an overview of this 
literature follows. 
It should be noted that comparison of efficacy is 
different from comparing the potency of two agents. 
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In comparisons of potency, several doses may be 
compared for each drug, withdrawal studies may also 
be performed and m inimal effective doses analysed. 
This paper compares efficacy of commonly used 
dosages and only includes those studies in which a 
direct comparison was made between budesonide and 
BDP It is also noted that several other sources could 
be used in this efficacy comparison. Biochemical 
studies such as receptor binding, placebo-controlled 
single-drug efficacy studies and other comparisons 
between either of these two agents and other commonly 
used inhaled corticosteroids could be included. This 
review examines only studies directly comparing the 
efficacy of budesonide and BDP 
Experience in Adults 
The majority of studies comparing the efficacy of 
inhaled BDP and budesonide in adult asthma patients 
have been randomised and used a cross-over design. In 
most studies, a combination of objective [peak expira- 
tory flow rate (PEFR), forced expiratory volume in 1 s 
(FEV,), forced vital capacity (FVC)] and subjective 
(symptom recording in a diary) variables have been 
used to assess efficacy. These studies are inadequate 
for conclusive decisions regarding comparative 
efficacy between BDP and budesonide for several rea- 
sons. The treatment periods have generally been of 
I 6 weeks in duration and not all studies have included 
a wash-out period prior to study treatment. The 
method of drug delivery has also differed within and 
between studies. Earlier studies comparing these two 
agents employed metered dose inhalers (MDIs), used 
with and/or without a spacer device. More recently, 
dry powder formulations of these drugs have been 
compared. 
STANDARD DOSAGES 
The conventional dosage for BDP and budesonide is 
between 200 and 800 pg daily, usually administered in 
two or four divided doses. The results of studies 
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comparing standard dosages of inhaled budesonide 
and BDP in adults are provided in Table 1 (5-18). The 
majority of these studies detected no statistically 
significant differences in efficacy between budesonide 
and BDP administered at the same dosage. 
Comparing MDIs without spacer devices, Bjorkander 
et al. (5) reported equivalent efficacy for budesonide 
and BDP both administered at 400 yg daily, and 
Stiksa et al. (16) found similar results at 800 p.g daily. 
One study utilising budesonide and BDP 400 ug daily 
via MD1 in 26 patients with steroid-dependent 
asthma reported that BDP allowed a significant 
reduction in oral steroid dosage compared with 
budesonide, without any decrease in pulmonary func- 
tion (13). Lopez et al. (11) reported a significantly 
greater improvement in lung function (assessed by 
spirometry) with budesonide than with BDP 800 lr.g 
daily by MDI. However, in this study all 15 patients 
received budesonide as the second treatment and 
there was no wash-out period between the treatments. 
Lung function would be expected to improve with 
progressive inhaled steroid treatment over several 
weeks (19). 
Older studies compared budesonide via MD1 plus a 
spacer device with BDP via MD1 without spacer; the 
results have not been in agreement. Three studies 
found no difference between budesonide plus spacer 
and BDP at dosages of 400 l.r.g daily (10,18) or 800 ug 
daily (15), whereas another study found budesonide 
200 pg daily via MD1 plus spacer to be significantly 
better than BDP 400 ug daily via MD1 alone (5). 
With respect to the dry powder formulations, Hill 
and Higgins (9) found no difference in efficacy when 
budesonide and BDP were administered at 400 yg 
daily, and other investigators reported equivalent effi- 
cacy at 800 pg daily dosages for both drugs (8,12). In 
each of two other studies comparing equal dosages of 
the dry powder formulations, the two drugs were equal 
for most assessment variables, but budesonide was 
found to be significantly more effective than BDP 
according to one variable: mid-expiratory flow at 50% 
of forced vital capacity (6) or PEFR (7). 
HIGH DOSAGES 
The use of dosages of BDP and budesonide in the 
range 1000-2000 I.rg day-i is becoming more common 
as data accumulate regarding the efficacy and toler- 
ability of such regimens. The results of studies com- 
paring high dosages of inhaled budesonide and BDP 
are summarised in Table 2 (20-26). 
In double-blind, cross-over studies that included 28 
and 36 patients, respectively, Ebden et al. (22) and 
Svendsen et al. (26) detected no statistically significant 
differences in lung function test results between budes- 
onide 800 l.rg twice daily and BDP 750 pg twice daily. 
Similarly, Selroos and Halme (25), in an open, 24 
month, parallel-group study found budesonide 600 ug 
twice daily to be of equivalent efficacy to BDP 500 ug 
twice daily, in 24 asthma patients using MDIs with 
and without spacer devices. Boe et al. (20) performed 
a larger, double-blind, cross-over study involving 128 
patients whose symptoms were not controlled by 
400 lrg of inhaled steroids. BDP 200 ug twice daily vs. 
budesonide 200 ug twice daily and BDP 500 ug twice 
daily vs. budesonide 400 ug twice daily were compared 
but the treatment period was only 4 weeks. No clini- 
cally significant differences in efficacy were observed 
between the two drugs at either dosage, or between 
high and low dosages of each drug. 
In contrast, in an open, randomised, parallel-group 
study in 146 patients, Brambilla et al. (21) found 
that the dosage of budesonide administered via 
Turbuhaler@ inhaler that was required to control 
asthma symptoms was lower than that of BDP 
administered via MD1 (200 kg budesonide for every 
250 pg BDP). Similarly, the results of two open, 
randomised, parallel-group studies showed that 
equivalent lung function and control of symptoms 
could be achieved using an almost 50% lower dosage 
of budesonide administered using a Turbuhaler@ 
inhaler compared with BDP administered by MD1 
plus a spacer device (23,24). 
Experience in Children 
Comparative studies of inhaled BDP and budesonide 
in asthmatic children are limited in number (Table 3) 
(27-30). In two double-blind, randomised, cross-over 
trials, budesonide (used with spacer) and BDP, both 
administered at a dosage of 400 ug daily for 1 month, 
provided similar efficacy as measured by twice daily 
PEFRs and recorded symptoms (28,30). Both BDP 
and budesonide 400 l.rg daily significantly improved 
lung function tests in 12 children after 2 weeks of 
treatment; no clinically significant differences in effi- 
cacy between the two drugs were noted (29). Baran 
(27) compared budesonide (used with spacer) and 
BDP, 100 I.rg twice daily for 3 weeks, in a double-blind, 
cross-over trial in 21 children. Morning and evening 
PEFR values were significantly higher with budes- 
onide treatment; however, FEV, values for the two 
regimens were not significantly different. 
Thus, in three of four studies in paediatric patients 
with asthma, BDP and budesonide were found to be 
equivalent in efficacy (28-30); values for PEFR but 
not FEV, were significantly higher with budesonide in 
one study (27). 
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Method of Delivery 
The method of delivery of inhaled corticosteroid may 
influence drug disposition and, therefore, efficacy. 
Method of delivery is very difficult, if not impossible, to 
analyse in a blinded fashion. After local adverse effects 
were recognised, spacer devices were developed in the 
late 1970s to decrease these effects and to increase drug 
delivery to the lungs. Budesonide was developed about 
this time, long after BDP (without spacer) was being 
used routinely. Spacer devices are recommended to 
avoid patient difficulties in the usage of an MD1 and to 
minimise the risk of local adverse effects, such as oral 
candidiasis. It is difficult to standardise techniques with 
spacer devices, however, and there is still insufficient 
information regarding how factors such as static charge 
affect drug delivery from spacers (3 1). 
Chlorofluorocarbon-containing MDls are gradu- 
ally being phased out in order to comply with the 
United Nations Environmental Programme. Dry 
powder formulations of budesonide (TurbuhalerB) 
and BDP (RotahalerB or DiskhalerB) are being pre- 
scribed more frequently. Although some researchers 
have reported a standard dosage of the dry powder 
form of budesonide to be superior to the same 
dosage of the dry powder form of BDP, according to 
one or more efficacy measurements (6,7,17), this 
finding has not been consistent between studies and 
equivalent efficacy has been demonstrated (9,12). 
Apart from efficacy, patient preference and ease of 
use may have an effect on clinical outcome. Although 
not well controlled, in several studies patients have indi- 
cated a preference for the TurbuhalerB vs. the 
RotahalerB inhaler with regard to ease of use (7,9,17). 
However, patients’ perception of ease of use cannot be 
equated with correct usage of the device. In a study by 
Watson (32), 96% of patients considered a TurbuhalerB 
inhaler easy to use but only 82% carried out all stages of 
the operation correctly. A pharmacy-based study where 
patients who were ‘experienced’ TurbuhalerB users 
were reviewed for their technique found that only 53% 
of patients used the device correctly (33). In this study 
the most common error (112 patients; 40%) was failure 
to load the TurbuhalerB in the upright position. 
Interestingly, in a study of 126 patients with asthma, a 
BDP DiskhalerB was found to enable more accurate 
recording of medication usage compared with the 
budesonide TurbuhalerB (82% VS. 48% of patients 
recorded drug usage accurately, P < O.OOl), and 
significantly more patients were confident that they 
were receiving the full dose of medication from the 
Diskhale@ inhaler (34). Therefore, both the 
TurbuhalerB and the DiskhalerB or RotahalerB 
inhalers may offer particular advantages but there are 
no convincing data for one device being superior. 
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Conclusions and Recommendations 
The comparative studies of inhaled BDP and budes- 
onide conducted to date generally have included small 
numbers of patients (~40) and short treatment periods 
(56 weeks). These studies were not designed to analyse 
carefully the relative potency of the two agents, rather 
the relative efficacy of specific doses of each. 
Moreover, in some studies, differences in the inhala- 
tion device used for BDP vs. budesonide may have had 
an influence on the percentage of dose reaching the 
target site and, subsequently, on the efficacy. While 
acknowledging these caveats, overall the studies con- 
sistently indicate that commonly prescribed dosages of 
inhaled BDP and budesonide administered using the 
same form of delivery have similar efficacy in adult 
and paediatric patients with asthma. Budesonide 
administered as a dry powder (TurbuhalerB) appears 
to be more potent on a milligram-per-milligram basis 
than BDP administered via MD1 plus a spacer device. 
The confirmation of the safety and efficacy of 
inhaled corticosteroids coupled with the recognition 
of the importance of pulmonary mucosal inflamma- 
tion in asthma has appropriately resulted in a major 
improvement in asthma control for most patients. As a 
wider array of corticosteroid preparations, delivery 
systems and approved dosages become available, fur- 
ther studies of comparative potency, efficacy, adverse 
effects and cost of treatment will help the clinician to 
make rational therapeutic decisions. At present, there 
is no convincing evidence that newer, more expensive, 
agents have superior efficacy to BDP in most asthma 
patients. 
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